[Table_Reportdate] 2025年08月26日 [证券分析师： Table_Authors] 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 ➢ 1.券商分类评价规定修订落地，关注中报配置窗口期——非银金融行业周报（20250818- 20250824） ➢ 2.开立医疗（300633）：静待招投标持续复苏，高端产品驱动未来增长——公司简评报告 ➢ 3.恒力石化（600346）：石化周期底部盈利暂时承压，"反内卷"下龙头优势有望凸显—— 公司简评报告 ➢ 4.特宝生物（688278）：业绩持续高增长，积极拓展创新技术平台——公司简评报告 ➢ 5.国产芯片新机遇，小米业绩亮眼迎新高——电子行业周报2025/8/18-2025/8/24 方霁 S0630523060001 fangji@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20250826 [tabl ...

晨会纪要 证券研究报告 2025 年 08 月 26 日 核心结论 【电子】汇顶科技(603160.SH) 2025 年半年报点评:多点布局新品持续 放量，旺季催化看好业绩增长 公司是指纹传感器全球领先企业，覆盖"传感、AI 计算、连接、安全"四大 核心业务,成长动力充足。我们预计汇顶科技 2025-2027 年营收分别为 55.24、65.8、78.4 亿元，归母净利润分别为 8.56、10.78、12.68 亿元。我 们持续看好公司未来业务拓展及业绩增长,维持"买入"评级。 【电子】聚辰股份（688123.SH）2025 年半年报点评：DDR5 SPD 与车规 EEPROM 齐放量,利润率显著提升 我们预计公司 25/26/27 年营收分别为 13.09/17.95/24.03 亿元,归母净利润 分别为 4.42/6.32/8.67 亿元，维持"买入"评级。 【传媒】芒果超媒（300413.SZ）2025 年上半年业绩点评: 芒果 TV 表现相 对稳定,看好新政下平台发展 我们预计公司 25-27 年归母净利润分别为 14.47/15.10/18.95 亿元, YoY+6%/+4%/+25%，内容储备丰富 ...

[Table_Reportdate] 2025年08月25日 [Table_invest] 买入（维持） 报告原因：业绩点评 [特宝Table_NewTitle] 生物（688278）：业绩持续高增长， 积极拓展创新技术平台 ——公司简评报告 [table_main] 投资要点 ➢ 风险提示：新产品商业化推广不及预期风险；研发进展不及预期风险；市场竞争加剧风险。 | [盈利预测与估值简表 Table_profits] | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 2022A | 2023A | 2024A | 2025E | 2026E | 2027E | | 营业总收入（百万元） | 1527 | 2100 | 2817 | 3734 | 4960 | 6364 | | 增长率（%） | 34.86% | 37.55% | 34.13% | 32.54% | 32.85% | 28.30% | | 归母净利润（百万元） | 287 | 555 | 828 | 1092 | 1456 | 1883 | | 增长率（%） | 58.4 ...

Market Strategy - The market is experiencing fluctuations and differentiation, with notable adjustments in high-position stocks [5][7] - The overall performance of blue-chip stocks is leading, while innovative small and medium enterprises are lagging behind [7][8] Economic Insights - From January to July, the online retail sales of agricultural products increased by 7.4% year-on-year [14][15] - The People's Bank of China conducted a 7-day reverse repurchase operation of 253 billion yuan on August 21, with a net injection of 124.3 billion yuan for the day [16][17] - A total of 20 distressed real estate companies have been approved for debt restructuring, with a total debt resolution scale exceeding 1.2 trillion yuan [18][19] Industry Dynamics - In July, China's engineering machinery import and export trade amounted to 5.504 billion USD, a year-on-year increase of 19.1% [27][28] - The total electricity consumption in July increased by 8.6% year-on-year, with residential electricity consumption growing significantly [29][30] Company Performance Tracking - Salted Fish (002847.SZ) reported a 19.58% increase in revenue and a 16.70% increase in net profit for the first half of 2025 [31][32] - TeBao Bio (688278.SH) achieved a non-net profit of 431 million yuan in the first half of 2025, a year-on-year increase of 30.68% [34] - Shangtai Technology (001301.SZ) reported a 34.37% increase in net profit for the first half of 2025 [36] - JiBit (603444.SH) achieved a net profit of 645 million yuan in the first half of 2025, a year-on-year increase of 24.50% [38] - LiYuanHeng (688499) reported a revenue of 1.529 billion yuan in the first half of 2025, turning a profit with a net profit of 33.41 million yuan [41][42] - JiuZhiTang (000989.SZ) reported a net profit of 144 million yuan in the first half of 2025, a year-on-year decrease of 29.71% [43][44]

Core Viewpoint - The stock price of TEBIO Biotechnology is currently at 89.50 yuan, reflecting a decline of 1.36% from the previous trading day, with a trading volume of 4.91 billion yuan [1] Company Overview - TEBIO Biotechnology focuses on the research and production of biological products, with key products including pegylated interferon α, which is used for the treatment of hepatitis B and other viral hepatitis [1] - The company operates in sectors such as biological products and hepatitis concepts [1] Market Potential - The clinical cure market for hepatitis B has significant potential, with approximately 75 million hepatitis B virus carriers in China and 260 million globally [1] - Pegylated interferon α is one of the core drugs for the clinical cure of hepatitis B, and TEBIO's products, including Pegbivirin, hold an important position in the market [1] Financial Performance - In the first quarter of this year, the company's net profit attributable to shareholders increased by 41.4% year-on-year, primarily driven by growth in sales revenue of core products and cost optimization [1] - On August 4, TEBIO experienced a net inflow of 26.27 million yuan in main funds, although there was an overall net outflow of 153 million yuan in the past five days [1]

Core Insights - The article highlights that only 13 women globally have become billionaires by founding healthcare companies, with 7 of them from China, indicating a significant presence of Chinese female entrepreneurs in the healthcare sector [1][3]. Industry Overview - The Chinese biopharmaceutical industry is experiencing a transformative phase, referred to as the "DeepSeek moment," as it evolves from being a "generic drug powerhouse" to a competitive force against Western innovation in pharmaceuticals [2]. - In 2024, over 1,250 new drug candidates are expected to enter the research and development phase in China, surpassing the European Union and nearly matching the United States' 1,440 candidates [2]. - Nearly one-third of the drug candidates licensed by large pharmaceutical companies in 2024 are from Chinese firms, a significant increase from zero in 2019 [3]. Company Highlights - **Hansoh Pharmaceutical Group**: Founded by Zhong Huijuan, the company reported a total revenue of approximately 12.26 billion yuan in 2024, with a year-on-year growth of about 21.3% [7]. - **Aimeike**: Founded by Jian Jun, the company specializes in hyaluronic acid production and was listed on the A-share market in 2020, achieving a market value exceeding 170 billion yuan [10]. - **Qizheng Tibetan Medicine**: Founded by Lei Jufang, the company generated sales revenue of 1.655 billion yuan in 2024, with a year-on-year growth of 16.31% [14]. - **Haisco Pharmaceutical Group**: Co-founded by Fan Xiulian, the company reported a revenue of 3.721 billion yuan in 2024, with a year-on-year increase of 10.92% [17]. - **Teva Biopharmaceuticals**: Founded by Yang Ying, the company has shown rapid growth, with revenues increasing from 1.527 billion yuan in 2022 to 2.817 billion yuan in 2024 [18]. - **Kangfang Biopharmaceutical**: Founded by Xia Yu, the company has developed several innovative drugs and is recognized for its leading position in the biopharmaceutical sector [23]. - **Xinlitai**: Co-founded by Liao Qingqing, the company has shifted focus to self-research and development, achieving a revenue of 4.012 billion yuan in 2024, with a year-on-year growth of 19.22% [26].

Core Viewpoint - The approval of Yipeisheng (益佩生), a long-acting growth hormone injection by Tebao Biopharma, marks a significant shift in the long-acting growth hormone market, breaking the decade-long monopoly held by Jinsai Pharmaceutical [2][4]. Company Summary - Tebao Biopharma's Yipeisheng is designed for weekly administration, targeting growth hormone deficiency in children aged three and above, enhancing patient compliance and reducing treatment burden [2][3]. - The company reported a revenue of 2.817 billion yuan in 2024, a year-on-year increase of 34.13%, and a net profit of 828 million yuan, up 49% year-on-year [6]. - The company has five existing products, with Paigebin being the main revenue driver, generating 2.447 billion yuan, accounting for over 80% of total revenue [6]. Industry Summary - The long-acting growth hormone market has been dominated by Jinsai Pharmaceutical for over ten years, with its product "Jinsai Zeng" being the first globally approved long-acting growth hormone [3][4]. - The market for growth hormone treatment in China is significant, with approximately 6.4 million children affected by growth hormone deficiency, indicating a substantial unmet medical need [3]. - The entry of Yipeisheng is expected to intensify competition in the long-acting growth hormone sector, potentially leading to expanded indications and increased market share for long-acting products [4].

Core Viewpoint - Teabo Bio's performance continues to grow significantly in the hepatitis B field, with a strong increase in revenue and net profit in Q1 2025 compared to the previous year [1][2]. Financial Performance - In Q1 2025, Teabo Bio achieved revenue of 673 million yuan, a year-on-year increase of 23.48%, and a net profit of 182 million yuan, up 41.4% [1]. - From 2020 to 2024, the company's revenue grew from 794 million yuan to 2.817 billion yuan, while net profit increased from 117 million yuan to 828 million yuan [2]. - The company has maintained a continuous dual increase in revenue and net profit for seven consecutive years, with a cumulative net profit of 1.968 billion yuan since its IPO [2]. Product Development - The growth in performance is attributed to the stable sales of the key product, Peginterferon, which is a first-in-class drug with complete independent intellectual property rights [2]. - Teabo Bio has invested significantly in R&D, with expenditures rising from 76.68 million yuan in 2020 to 295 million yuan in 2024, totaling 833 million yuan over the five years [2]. Intellectual Property and Market Position - As of the end of 2024, Teabo Bio has obtained 16 invention patents and a total of 293 intellectual property rights [3]. - The company has made important progress in multiple R&D projects, including the acceptance of a drug registration application for its self-developed growth hormone injection in January 2024 [3]. Stock Performance - Teabo Bio's stock price has seen a significant increase, rising from an IPO price of 8.24 yuan per share to 78.96 yuan per share as of April 22, representing a cumulative increase of 858.25% [3].

Summary of Conference Call Company and Industry - The conference call primarily discusses **特保生物 (TeBao Bio)**, a company in the **pharmaceutical industry**, focusing on **clinical cures for hepatitis B** and related treatments. Key Points and Arguments 1. **Financial Performance**: - The company reported a **net profit of 828 million yuan**, a **49% increase year-over-year**. The **deducted net profit** was **827 million yuan**, reflecting a **42.73% growth**. This performance is attributed to the increasing recognition of their product, **派格宾 (Pegbivac)**, in the market and improved management efficiency, leading to a reduction in overall expense ratios and enhanced profitability [2][3][21]. 2. **Product Development**: - The company is focusing on **immunology and metabolic diseases**, with ongoing research and development projects. Notably, **Pegbivac** has received clinical trial approvals for new indications, including **clinical cure for hepatitis B** and applications in treating **thrombocytopenia** [3][11][14]. 3. **Clinical Trials and Regulatory Approvals**: - The company submitted an **NDA (New Drug Application)** for **Pegbivac** in March 2024, which is currently under review. This submission is significant as it is the first global NDA for a clinical cure for hepatitis B [5][10][11]. 4. **Market Penetration and Treatment Efficacy**: - The penetration rate of antiviral treatments remains low, indicating a substantial market opportunity. The company believes that as scientific understanding and treatment options improve, the acceptance and demand for hepatitis B treatments will increase [20][21][24]. 5. **Collaborations and Partnerships**: - The company has established collaborations with various organizations, including **九天生物 (Nine Sky Bio)**, to enhance its product pipeline and leverage advanced technologies in gene therapy and immunotherapy [14][25]. 6. **Future Outlook**: - The management expressed confidence in becoming a leader in the field of clinical cures for hepatitis B and related diseases. They anticipate continued growth in R&D investments aligned with project needs and market demands [11][37]. Other Important but Possibly Overlooked Content 1. **Sales Strategy**: - There is a focus on expanding the sales team in anticipation of product approvals, although the current hiring pace is cautious due to pending regulatory approvals [36]. 2. **Research and Development Focus**: - The company emphasizes that R&D investments will be driven by the need to solve clinical problems rather than merely increasing the number of projects. This strategic approach aims to ensure that resources are allocated effectively to high-potential areas [37]. 3. **Patient Engagement and Market Dynamics**: - The management highlighted the importance of educating patients and healthcare providers about the benefits of achieving clinical cures for hepatitis B, which could drive demand and acceptance in the market [30][32]. 4. **Long-term Vision**: - The company aims to address the broader population of hepatitis B patients, including those in non-active phases, by enhancing treatment options and improving patient outcomes through innovative therapies [29][31]. This summary encapsulates the critical insights from the conference call, reflecting the company's strategic direction, financial health, and market opportunities within the pharmaceutical industry.

Core Viewpoint - The company is actively advancing its clinical research and product pipeline in the field of chronic hepatitis B treatment, particularly focusing on the approval and market penetration of its drug, Paigebin, and its combination therapies [2][3]. Group 1: Clinical Developments - The latest approval timeline for the clinical cure indication for chronic hepatitis B is expected to be submitted to the National Medical Products Administration in March 2024, currently under technical review [2]. - The establishment of clinical cure outpatient clinics is ongoing, which is anticipated to positively impact sales by enhancing treatment standardization and increasing patient awareness [2]. - The company is also progressing with the registration application for its growth hormone product, which was accepted in January 2024 and is currently under technical review [2]. Group 2: Research and Development Strategy - The company plans to increase R&D investment in line with clinical needs, focusing on immunology and metabolism, with an upward trend in overall R&D spending as more projects enter clinical research [2][3]. - The company has established collaborations for various products, including ongoing preclinical studies and Phase I clinical trials, indicating a robust pipeline in liver disease and gene therapy [2][3]. Group 3: Market Insights and Future Outlook - The penetration rate of long-acting interferon in chronic hepatitis B treatment remains low, but the company believes that new therapies and combination strategies will increase the patient population receiving antiviral treatment [3]. - The company anticipates that the market for long-acting interferon will expand as new drugs for hepatitis B are launched, supported by evidence showing interferon’s effectiveness in reducing liver cancer risk [3]. - The company is exploring various real-world research projects to optimize hepatitis B treatment strategies, aiming to broaden the definition and scope of clinical cure populations [3].